ReviewClinical pharmacology and therapeutics2018
Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.
Review in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- The clinical effectiveness of sivelestat in treating sepsis patients with both acute respiratory distress syndrome and septic cardiomyopathy.Journal of cardiothoracic surgery · 2024Trial
- SIRT1 in acute lung injury: unraveling its pleiotropic functions and therapeutic development prospects.Molecular and cellular biochemistry · 2025Review
- Clinical Trials of Mesenchymal Stem Cells for the Treatment of COVID 19.Current stem cell research & therapy · 2024Review
- Review
- The Emerging Roles of Ferroptosis in Pathophysiology and Treatment of Acute Lung Injury.Journal of inflammation research · 2023Review
- Protective effect of ulinastatin on myocardial injuries in children with severe pneumonia.American journal of translational research · 2023Article
- 1,2,3,4,6-O-Pentagalloylglucose Protects against Acute Lung Injury by Activating the AMPK/PI3K/Akt/Nrf2 Pathway.International journal of molecular sciences · 2022Article
- Clinical Efficacy of Budesonide/Glycopyrronium Bromide/Formoterol in the Treatment of Patients with Acute Respiratory Distress Syndrome and Its Effect on Inflammatory Factors.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Predicting candidate therapeutic drugs for sepsis-induced acute respiratory distress syndrome based on transcriptome profiling.Bioengineered · 2021Article
- Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design.Acta pharmaceutica Sinica. B · 2021Review
- Delayed anaphylaxis due to gadolinium- A rare clinical scenario.Radiology case reports · 2021Article
- Acute lung injury - from pathophysiology to treatment.Physiological research · 2020Review
- Late-onset acute respiratory distress syndrome induced by a gadolinium-based contrast agent.Respiratory medicine case reports · 2020Article
- Microphysiological systems modeling acute respiratory distress syndrome that capture mechanical force-induced injury-inflammation-repair.APL bioengineering · 2019Review
- A CRTH2 antagonist, CT-133, suppresses NF-κB signalling to relieve lipopolysaccharide-induced acute lung injury.European journal of pharmacology · 2019Article
- Acute respiratory distress syndrome after the use of gadolinium contrast agent.Respiratory medicine case reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite 50 years of extensive research, no definite drug is currently available to treat acute respiratory distress syndrome (ARDS), and the supportive therapies remain the mainstay of treatment. To improve drug development for ARDS, researchers need to deeply analyze the "omics" approaches, reevaluate the suitable therapeutic targets, resolve the problems of inadequate animal modeling, develop the strategies to reduce the heterogeneity, and reconsider new therapeutic and analytical approaches for better designs of clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.